Literature DB >> 22034865

Targeting metastatic melanoma.

Keith T Flaherty1.   

Abstract

Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22034865     DOI： 10.1146/annurev-med-050410-105655

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  23 in total

1.  [BRAF mutation detection in metastatic melanoma].

Authors:  M Dietel; A Enk; A Lehmann; J Bauer; C Garbe; U Kellner; T Kirchner; A Jung; H Kreipe; S Merkelbach-Bruse; R Büttner; J Rüschoff; W Schlake; P Schirmacher; R Penzel; R Stadler
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

2.  Skin Tone Dissatisfaction, Sun Exposure, and Sun Protection in Australian Adolescents.

Authors:  Amanda D Hutchinson; Ivanka Prichard; Kerry Ettridge; Carlene Wilson
Journal:  Int J Behav Med       Date:  2015-08

3.  A quantitative method for screening and identifying molecular targets for nanomedicine.

Authors:  Peng Guo; Jiang Yang; Diane R Bielenberg; Deborah Dillon; David Zurakowski; Marsha A Moses; Debra T Auguste
Journal:  J Control Release       Date:  2017-03-22       Impact factor: 9.776

Review 4.  Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.

Authors:  Francesca Carlomagno; Mario Chiariello
Journal:  J Mol Med (Berl)       Date:  2014-06-08       Impact factor: 4.599

5.  Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Tae-Kang Kim; Adam C Wright; Laura N Grese; Samuel J Riney; Minh N Nguyen; Robert C Tuckey
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

6.  Ethanol extract of Ilex hainanensis Merr. exhibits anti-melanoma activity by induction of G1/S cell-cycle arrest and apoptosis.

Authors:  Ya-Qi Zhang; Hao Yang; Wei-Dong Sun; Juan Wang; Bao-Yuan Zhang; Yan-Jun Shen; Min-Qiang Yin; Yun-Xing Liu; Chang Liu; Yun Sun
Journal:  Chin J Integr Med       Date:  2017-07-25       Impact factor: 1.978

7.  EWI-2 negatively regulates TGF-β signaling leading to altered melanoma growth and metastasis.

Authors:  Hong-Xing Wang; Chandan Sharma; Konstantin Knoblich; Scott R Granter; Martin E Hemler
Journal:  Cell Res       Date:  2015-02-06       Impact factor: 25.617

8.  Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.

Authors:  Yongmei Feng; Eric Lau; Marzia Scortegagna; Chelsea Ruller; Surya K De; Elisa Barile; Stan Krajewski; Pedro Aza-Blanc; Roy Williams; Anthony B Pinkerton; Michael Jackson; Lynda Chin; Maurizio Pellecchia; Marcus Bosenberg; Ze'ev A Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2012-11-02       Impact factor: 4.693

Review 9.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

10.  Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.

Authors:  Jin Wang; Jianjun Chen; Duane D Miller; Wei Li
Journal:  Mol Cancer Ther       Date:  2013-11-18       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.